Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Germline Mutation”

147 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 147 results

Testing effectiveness (Phase 2)Study completedNCT02789332
What this trial is testing

Assessing the Efficacy of Paclitaxel and Olaparib in Comparison to Paclitaxel / Carboplatin Followed by Epirubicin/Cyclophosphamide as Neoadjuvant Chemotherapy in Patients With HER2-negative Early Breast Cancer and Homologous Recombination Deficiency

Who this might be right for
Breast CancerTriple Negative Breast NeoplasmsHRpos Breast Neoplasms+1 more
GBG Forschungs GmbH 107
Early research (Phase 1)Ended earlyNCT02561832
What this trial is testing

A Phase I, Open-Label, 2 Part Multicentre Study to Assess the Safety and Efficacy of Olaparib in Combination With Carboplatin in Patients With Advanced HER-2 Negative Breast Cancer

Who this might be right for
Breast Cancer
AstraZeneca 15
Testing effectiveness (Phase 2)Active Not RecruitingNCT03344965
What this trial is testing

Olaparib In Metastatic Breast Cancer

Who this might be right for
Metastatic Breast CancerInvasive Breast CancerSomatic Mutation Breast Cancer (BRCA1)+7 more
Beth Israel Deaconess Medical Center 114
Large-scale testing (Phase 3)Study completedNCT02282020
What this trial is testing

Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments

Who this might be right for
Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity
AstraZeneca 266
Testing effectiveness (Phase 2)WithdrawnNCT06080165
What this trial is testing

Sirolimus for Improving Social Abilities in People With PTEN Germline Mutations

Who this might be right for
PTEN Gene MutationPTEN Hamartoma Tumor SyndromePTEN Hamartoma Syndrome
Stanford University
Not applicableLooking for participantsNCT01247597
What this trial is testing

DICER1-related Pleuropulmonary Blastoma Cancer Predisposition Syndrome: A Natural History Study

Who this might be right for
Pleuropulmonary BlastomaCystic NephromaOvarian Sertoli-Leydig Cell Tumors+2 more
National Cancer Institute (NCI) 1,500
Testing effectiveness (Phase 2)Looking for participantsNCT04090567
What this trial is testing

Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer

Who this might be right for
Advanced Breast CarcinomaAnatomic Stage III Breast Cancer AJCC v8Anatomic Stage IIIA Breast Cancer AJCC v8+12 more
M.D. Anderson Cancer Center 60
Testing effectiveness (Phase 2)Ended earlyNCT02034916
What this trial is testing

A Phase 2, 2-Stage, 2-Cohort Study of Talazoparib (BMN 673), in Locally Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (ABRAZO Study)

Who this might be right for
Breast NeoplasmsBRCA 1 Gene MutationBRCA 2 Gene Mutation
Pfizer 84
Not applicableLooking for participantsNCT03830229
What this trial is testing

Long Term Follow-up of Mesothelioma Patients and Their Family Members With Germline Mutations in BAP1 and Other Genes

Who this might be right for
MesotheliomaFamilies
National Cancer Institute (NCI) 1,000
Testing effectiveness (Phase 2)Active Not RecruitingNCT05203445
What this trial is testing

Olaparib and Pembrolizumab in People With Triple Negative Breast Cancer (TNBC) or Hormone Receptor-positive HER2-negative Breast Cancer

Who this might be right for
Breast Cancer
Memorial Sloan Kettering Cancer Center 23
Not applicableLooking for participantsNCT04431024
What this trial is testing

Prospective Evaluation of High Resolution Dual Energy Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and Minimally Invasive Surgical Surveillance for Early Detection of Mesotheliomas in Patients With BAP1 Tumor Predisposition Syndrome

Who this might be right for
Familial CancerBRCA1-Associated Protein-1 (BAP1) MutationsTumor Predisposition Syndrome (TPDS)+1 more
National Cancer Institute (NCI) 800
Not applicableStudy completedNCT03982446
What this trial is testing

Germline Mutations in Pancreatic Adenocarcinoma

Who this might be right for
Germline Mutation AbnormalityPancreatic CancerPredisposition, Genetic+1 more
Hellenic Cooperative Oncology Group 549
Testing effectiveness (Phase 2)Study completedNCT04493060
What this trial is testing

Niraparib and Dostarlimab for the Treatment of Germline or Somatic BRCA1/2 and PALB2 Mutated Metastatic Pancreatic Cancer

Who this might be right for
Metastatic Pancreatic Ductal AdenocarcinomaStage IV Pancreatic Cancer AJCC v8
Mayo Clinic 22
Not applicableLooking for participantsNCT02302742
What this trial is testing

Triple Negative Breast Cancer and Germline Hereditary Breast and Ovarian Cancer Mutation Carrier Registry

Who this might be right for
Breast CancerHereditary Breast and Ovarian Cancer
University of Kansas Medical Center 1,500
Not applicableActive Not RecruitingNCT03246841
What this trial is testing

Investigation of Tumour Spectrum of Germline Mutations in Breast and Ovarian Cancer Genes.

Who this might be right for
Hereditary Breast and Ovarian CancerMutation
UNICANCER 7,274
Post-approval studies (Phase 4)Study completedNCT02476968
What this trial is testing

To Assess the Efficacy and Safety of Olaparib Maintenance Monotherapy in the Treatment of Ovarian Cancer

Who this might be right for
BRCA or HRR+ Mutated Ovarian Cancer Patients
AstraZeneca 181
Testing effectiveness (Phase 2)Active Not RecruitingNCT03330847
What this trial is testing

To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.

Who this might be right for
Metastatic Triple Negative Breast Cancer
AstraZeneca 273
Testing effectiveness (Phase 2)Active Not RecruitingNCT04548752
What this trial is testing

Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations

Who this might be right for
Metastatic Pancreatic AdenocarcinomaStage IV Pancreatic Cancer AJCC v8
National Cancer Institute (NCI) 88
Testing effectiveness (Phase 2)Ended earlyNCT03499353
What this trial is testing

Talazoparib For Neoadjuvant Treatment Of Germline BRCA1/2 Mutation Patients With Early Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer

Who this might be right for
Early Breast Cancer
Pfizer 61
Large-scale testing (Phase 3)Study completedNCT03402841
What this trial is testing

Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed Non gBRCAm Ovarian Cancer Patients

Who this might be right for
Non-Germline BRCA Mutated Ovarian Cancer
AstraZeneca 279
Load More Results